Global /United States /Healthcare /Biotechnology /KRON

Kronos Bio, Inc.

KRON

• NASDAQ: KRON • Delayed

0.8701USD -1.1%

As of 14 June 2026, Kronos Bio, Inc. has a market cap of $53.12M USD, ranking #30165 globally and #4426 in the United States. It ranks #2734 in the Healthcare sector, and #529 in the Biotechnology industry.

Global Rank

30165

Country Rank

4426

Sector Rank

2734

Industry Rank

529

Key Stats

Market Cap

$53.12MUSD

Enterprise Value

-$21.92MUSD

Revenue (TTM)

$9.19MUSD

EBITDA (TTM)

-$49.14MUSD

Net Income (TTM)

-$64.49MUSD

PS Ratio

5.8

PB Ratio

0.7

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Biotechnology

CEO

Deborah Knobelman open_in_new

Employees

Founded

2017

IPO

09 Oct 2020

Website

kronosbio.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-1.1%	-2.5%	29%	-2.8%	-6.2%	-8.4%	-14%	-75%	-97%

News

KRON Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	KRON Kronos Bio Inc Ordinary Shares ISIN: US50107A1043 Shares Out.: Shares Outstanding: 60.969M¹ Shares Float: 39.445M² TV: TradingView: NASDAQ: KRON SA: Stock Analysis: NASDAQ: KRON YF: Yahoo Finance: KRON GF: Google Finance: NASDAQ: KRON NQ: NASDAQ: KRON BA: Barron's: KRON MS: Morningstar: XNAS: KRON	0.8701 USD	TV: TradingView: NASDAQ: KRON SA: Stock Analysis: NASDAQ: KRON YF: Yahoo Finance: KRON GF: Google Finance: NASDAQ: KRON NQ: NASDAQ: KRON BA: Barron's: KRON MS: Morningstar: XNAS: KRON

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Kronos Bio, Inc.

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics to treat cancer and other serious diseases in the United States. It is developing KB-9558, a p300 KAT inhibitor development candidate which is in preclinical development for the treatment of multiple myeloma, as well as HPV-driven tumors; and KB-7898, a p300 KAT inhibitor, which is in preclinical development for the treatment of Sjogren’s disease. The company was incorporated in 2017 and is headquartered in San Mateo, California.

Similar Companies

Industry: Biotechnology (United States)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 343K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 301K%	19.0	United States
Natera, Inc. NASDAQ: NTRA	$27.6B 52K%	-	United States
IQVIA Holdings Inc. NYSE: IQV	$26.3B 49K%	20.0	United States
United Therapeutics Corp. NASDAQ: UTHR	$25.03B 47K%	20.4	United States
Moderna, Inc. NASDAQ: MRNA	$18.13B 34K%	-	United States

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
argenx SE EBR: ARGX	$47.84B 41.39B EUR 90K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.84B 68.19T KRW 84K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.36B 60.27B AUD 80K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.3B 33.71B CHF 80K%	37.2	Switzerland
Celltrion, Inc. KRX: 068270	$28.11B 42.76T KRW 53K%	43.8	South Korea
BioNTech SE NASDAQ: BNTX	$25.69B 48K%	-	Germany

chevron_leftBack